Delivery of muscle relaxants through an inhalation route
First Claim
1. A method of treating musculoskeletal pain or restless leg syndrome in a patient comprising administering a therapeutic amount of a drug condensation aerosol to the patient by inhalation,wherein the drug is selected from the group consisting of quinine, chlorzoxazone, carisprodol and cyclobenzaprine, andwherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of muscle relaxants through an inhalation route. Specifically, it relates to aerosols containing muscle relaxants that are used in inhalation therapy. In a method aspect of the present invention, a muscle relaxant is delivered to a patient through an inhalation route. The method comprises: a) heating a coating of a muscle relaxant, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% muscle relaxant degradation products. In a kit aspect of the present invention, a kit for delivering a muscle relaxant through an inhalation route is provided which comprises: a) a coating of a muscle relaxant and b) a device for dispensing said coating a muscle relaxant as a condensation aerosol.
205 Citations
35 Claims
-
1. A method of treating musculoskeletal pain or restless leg syndrome in a patient comprising administering a therapeutic amount of a drug condensation aerosol to the patient by inhalation,
wherein the drug is selected from the group consisting of quinine, chlorzoxazone, carisprodol and cyclobenzaprine, and wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.
-
10. A method of administering a drug condensation aerosol to a patient, comprising administering the drug condensation aerosol to the patient by inhalation,
wherein the drug is selected from the group consisting of quinine, chlorzoxazone, carisprodol and cyclobenzaprine, and wherein the drug condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% durg degradation products by weight, and an MMAD of less than 5 microns.
-
11. A kit for delivering a drug condensation aerosol comprising:
-
a. a thin layer containing the drug, on a solid support, wherein the drug is selected from the group consisting of quinine, chlorzoxazone, carisprodol and cyclobenzaprine, and b. a device for providing the condensation aerosol, wherein the condensation aerosol is formed by heating the thin layer to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)
-
Specification